Business Wire

Panasonic State-of-the-Art Technology Meets Kabuki in Las Vegas


Panasonic Corporation is sponsoring and will provide technical support to the Japan KABUKI Festival in Las Vegas 2016 (produced by Shochiku Co., Ltd.), running from April 29 to May 7. Panasonic hopes to highlight a new approach to performing and enjoying Kabuki, the classical Japanese dance drama that dates back more than 400 years, by enlivening the performance of the art form with state-of-the-art technology to make it more engaging and accessible to contemporary entertainment seekers. Panasonic’s support includes the following initiatives:

This Smart News Release features multimedia. View the full release here:

‘KABUKI LION’–The Adventures of the Mythical Lion (Graphic: Business Wire)

‘KABUKI LION’–The Adventures of the Mythical Lion (Graphic: Business Wire)

A) Special sponsorship and technical support for the first theatrical performance of Kabuki in Las Vegas: “Panasonic presents Wonder KABUKI Spectacle ‘KABUKI LION’–The Adventures of the Mythical Lion”
Dates: May 3 to 7, 2016 (five days, six shows)
Venue: David Copperfield Theater at the MGM Grand Hotel
Technology Details: Theatrical video production using high-lumen projectors
Panasonic enjoys the world’s largest market share in high-performance, high-lumen projectors (5,000 lumens or more); Panasonic will deploy nine 20,000-lumen PT-DZ21K digital projectors to support the production in the David Copperfield Theater. By leveraging the projectors’ advanced features, including their high lumen output, ample energy savings, compact size, and high geometric adjustment technology, the projectors will help to enable a more engrossing production and dynamic video presentation.
Video production for this theatrical performance will be undertaken by NAKED, a popular avant-garde Japanese space creation company, directed by Ryotaro Muramatsu.

B) Trial of next-generation guest services at the technology showcase “KABUKI LION Interactive Showcase” in David Copperfield Theater’s Lobby
Dates: May 3 to 7, 2016 (five days)
Venue: Lobby of David Copperfield Theater
Technology Details:

(1) “3D KABUKI AVATAR” - Trial of interactive services for fans using innovative 3D scanner
Visitors will be able to take a 3D photo of themselves in the theater’s lobby, using a 3D scanner equipped with 54 Panasonic LUMIX digital cameras. The 3D photo can then be processed into either an original Kabuki figurine memento or a movie in which the avatar of the visitor dances just like a professional Kabuki actor. Information to visitors will also be provided using Panasonic’s original light ID technology, which enables the participant to collect additional information by placing their smartphones adjacent to a light terminal device. Also, selected participants may be invited to see the KABUKI show, where their avatar might play a role in a video that will be shown on stage.

(2) Trial of automated hotel services
Using an autonomous delivery robot that has already been put into commercial use at hospitals in Japan and overseas, a test demonstration will be held in which the sociable robot circulates round the lobby, advertising the KABUKI show and distributing free water to visitors.

C) Special sponsorship and technical support for one of the world’s largest water screen projections: “Panasonic presents ‘Water Screen Digital Show by Shochiku X teamLab’”
Dates: April 29 to May 7, 2016 (nine days)
Venue: Fountains of Bellagio, Las Vegas
Technology Details: On the artificial lake at the Bellagio thirteen 20,000-lumen PT-DZ21K projectors will digitally depict the tale of an aquatic Samurai battle using the fountains as a huge, 300meter wide screen. The video to be projected will be produced by teamLab, a digital creative company highly renowned worldwide for its art works based on digital technology, and directed by Toshiyuki Inoko.

This will be the second visit to Las Vegas by this collaborative project between Panasonic and Shochiku Co., Ltd., which began under the theme “fusion of tradition and state-of-the-art technology” in Las Vegas, following the debut last August of “Panasonic presents KABUKI Spectacle at Fountains of Bellagio ‘Koi-Tsukami’–Fight with a Carp.”

Panasonic Corporation Senior Managing Director Yasuji Enokido, who leads the company’s worldwide solutions business, commented on the company’s plans to further develop solutions for specific industries: “Providing solutions for the entertainment industry is one of Panasonic’s strategic businesses,” he said. “Stadiums, theme parks and theaters around the world are constantly searching for new ways to deliver a better fan experience, and expectations of what we can do as a technology partner are rising. In addition to event production using our highly-renowned projectors, Panasonic is working hard to provide deeper and more diverse value to the fan or showgoer, as you can tell from the technologies we are deploying as part of this Kabuki Festival.”

Satoshi Takeyasu, executive officer of Panasonic Corporation in charge of Corporate Communications, Advertising and CSR, said: “We respect and identify with the efforts of Kabuki professionals who uphold a wonderful tradition that spans over 400 years, and yet are constantly eager to innovate and try something new to help more people enjoy their art form. This is why we have continued to collaborate with Shochiku and MGM following the success of last August’s Kabuki event in Las Vegas. This time, we are incorporating additional technical trials too.” Turning his attention to the Olympics Games, Mr. Takeyasu commented: “2016 is the year of the Rio Olympics Games and the Paralympics, and Olympism is about promoting cultural appreciation as well as sports. After the Rio Games, it’s Tokyo’s turn and the efforts to promote Japanese culture throughout the world will draw greater attention to Japan’s capital city. Japanese culture is full of wonders and we hope to share this legacy with the world in innovative and surprising new ways, using our latest solutions technologies.”

News and information about the performances and trials in the theater’s lobby will be available on the following websites

[Japan KABUKI Festival in Las Vegas 2016] special site

Kabukibito (Shochiku Kabuki official website)

Related Links
Panasonic Projectors Bring to Life One of the World's Largest Water Screen Projections (2016/8/19)

(Video Report)
Kabuki Spectacle + Panasonic projectors @ Las Vegas

Contact information

Media Contact
Panasonic Corporation
Global Communications Department
Media Promotion Office

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52Pressemelding

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50Pressemelding

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00Pressemelding

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on

ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe23.3.2018 11:27Pressemelding

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. The 2-drug regimen comprises dolutegravir 50mg (ViiV Healthcare) and rilpivirine 25mg (Janssen Sciences Ireland UC). Deborah Waterhouse, Chief Executive Officer at ViiV Healthcare commented: “Today is an important milestone for people living with HIV in Europe. It takes us a step closer to offering the first, single-pill, 2-drug regi

Smiths Detection Hold Baggage Scanner Meets Highest Security Standards in EU23.3.2018 07:00Pressemelding

The Smiths Detection HI-SCAN 10080 XCT has achieved ECAC approval as a Standard 3.1 explosives detection system for hold baggage – the highest, defined security standard in the EU. This significant advance was made possible by using a dual-view, dual-energy line scanner with high resolution 3D Computed Tomography (CT) to deliver exceptional data. This press release features multimedia. View the full release here: Smiths Detection HI-SCAN 10080 XCT (Graphic: Business Wire) This achievement gives airports currently upgrading to Standard 3 technology, the option to increase detection levels even further to 3.1; and any standard 3 systems already installed can be easily elevated to 3.1 via a software upgrade. The detection algorithms are interchangeable on a bag by bag basis depending on the destination and associated risk level. This offers additional flexibility and productivity. “With the capability to meet detection requirements